Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® (EVIDENCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00658099
Recruitment Status : Completed
First Posted : April 14, 2008
Last Update Posted : January 31, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.

Condition or disease Intervention/treatment
Diabetes Diabetes Mellitus, Type 2 Drug: insulin detemir Drug: insulin NPH

Layout table for study information
Study Type : Observational
Actual Enrollment : 699 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Change in Weight on Insulin Detemir (Levemir®) or Isophane (NPH) Insulin (Insulatard®) in Patients With Type 2 Diabetes Mellitus
Study Start Date : November 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
A Drug: insulin detemir
Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation

B Drug: insulin NPH
Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation

Primary Outcome Measures :
  1. Change in weight [ Time Frame: after 6 months of treatment ]

Secondary Outcome Measures :
  1. The effect on metabolic control assessed by the changes in glycaemic parameters: HbA1c and blood glucose values [ Time Frame: after 6 months of treatment ]
  2. The incidence of hypoglycaemic events [ Time Frame: after 6 months of treatment ]
  3. Safety parameters by collecting (serious) adverse drug reactions, pregnancies and technical complaints. [ Time Frame: after 6 months of treatment ]
  4. The general well-being by using the WHO-5 well-being questionnaire. [ Time Frame: after 6 months of treatment ]
  5. The treatment satisfaction of subjects treated with insulin detemir or NPH insulin by using insulin treatment satisfaction questionnaire [ Time Frame: after 6 months of treatment ]
  6. The satisfaction of physicians who treat the subjects with either insulin detemir or NPH insulin by using 4 questions, which are included in CRF, at the final visit. [ Time Frame: after 6 months of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Type 2 diabetes patiens failing on oral anti-diabetic agents

Inclusion Criteria:

  • Type 2 diabetes
  • HbA1c greater than 7.0% and/or hypoglycaemia
  • variable FBG and/or weight increase
  • the selection of the subjects will be at the discretion of the participating physician

Exclusion Criteria:

  • non-type 2 diabetes
  • current treatment with Levemir® or Insulatard®
  • hypersensitivity to Levemir® or Insulatard® or to any of the excipients
  • women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00658099

Layout table for location information
Novo Nordisk Investigational Site
Bucharest, Romania, 010031
Sponsors and Collaborators
Novo Nordisk A/S
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Additional Information:
Publications of Results:
Doina Catrinoiu; Effect of Once-Daily Detemir vs NPH Insulin on Body Weight and Metabolic Control When Added to OADs in Type 2 Diabetes; 2029-PO; 69th Scientific Sessions (2009); American Diabetes Association

Layout table for additonal information
Responsible Party: Novo Nordisk A/S Identifier: NCT00658099    
Other Study ID Numbers: NN304-1976
First Posted: April 14, 2008    Key Record Dates
Last Update Posted: January 31, 2017
Last Verified: January 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin Detemir
Isophane Insulin, Human
Insulin, Isophane
Isophane insulin, beef
Hypoglycemic Agents
Physiological Effects of Drugs